Kota Yogyakarta

Researchers are evaluating whether the medicine tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after they were last seen well. This study focuses on people who had a stroke caused by a clot blocking blood flow in the brain and who have imaging showing brain tissue that can still be saved. Participants should not be planning to receive a procedure to remove the clot and must have a pre-stroke disability level of 0 or 1 on the modified Rankin Scale. Participants are randomly placed into two groups. One group receives a single injection of tenecteplase into a vein, while the other group receives standard medical care. The study includes adults aged 18 and over who had an acute stroke or woke up with stroke symptoms more than 4.5 hours ago. Imaging with MRI or CT is used to confirm eligibility. The study lasts about three months, starting with a hospital stay of about one week. During the study, participants have seven clinical examinations or visits to monitor their recovery and health. The last two visits may be done from home to allow remote assessments. Researchers use the modified Rankin Scale to measure disability or dependence in daily activities at 90 days after treatment. They also monitor for any side effects or health changes to compare the effects of tenecteplase against standard care.

Researchers are evaluating the accuracy of three transthoracic needle aspiration (TTNA) techniques—jabbing-then-suction, suction-with-jabbing, and suction-only—in patients suspected of having lung cancer. The study aims to compare the quality of tumor samples obtained by these different methods to determine if there are differences in sample accuracy. This research involves patients who require biopsy for lung cancer diagnosis and uses core needle biopsy as the gold standard for comparison. During hospitalization for diagnostic testing, each patient will undergo all three TTNA techniques and a core needle biopsy. These biopsies are performed in the operating room under local anesthesia with anesthesiologist supervision. The TTNA procedures are routine and not experimental. After the biopsy procedures, patients are monitored for at least 24 hours to observe any possible complications. Participants will be involved in the biopsy procedures and subsequent observation period. Researchers will assess the quality of the samples immediately after each biopsy procedure. Patient monitoring will include observation for complications during the 24-hour post-biopsy period. The total participation timeline includes the biopsy process and the following observation phase to ensure safety and collect data on sample quality.

Researchers are evaluating whether a home-based cardiac rehabilitation program with a family empowerment approach can help patients recovering from acute coronary syndrome (ACS). This study focuses on improving health-related quality of life and peak oxygen consumption (peak Vo2) compared to usual care. The trial includes adults aged 18 to 65 years who have experienced their first acute coronary event, with or without undergoing PCI, and who live with family members involved in their care. The intervention lasts 12 weeks and involves home-based cardiac rehabilitation that includes physical exercise, dietary management, smoking cessation, and stress management. Patients and their families receive educational materials, videos from health professionals, and guidance from facilitators to empower family involvement. Exercise sessions are done three times a week with family monitoring heart rate and symptoms. Follow-ups with cardiologists occur at weeks 1, 6, and 12, with nurse facilitators providing monitoring via video calls or home visits. Participants will perform walking exercises, follow diet and stress recommendations, quit smoking, and adhere to medications. They will visit clinics for cardiologist assessments and undergo a 6-minute walk test to measure peak Vo2. Families report daily on diet, exercise frequency, medication adherence, and exercise-related heart rate and symptoms through online forms. Researchers measure health-related quality of life and peak Vo2 from enrollment through the 12-week treatment period, with safety and progress closely monitored throughout.

This research aims to evaluate the use of honey as a treatment option for deep neck space abscesses, a serious condition in the field of ear, nose, and throat surgery that can lead to high illness rates, death, and expenses. The study compares honey dressing to standard wound care methods to see if honey can help wounds heal faster and control infection better, potentially lowering treatment costs. It is designed as a single-blind randomized clinical trial involving patients treated at a major hospital and other equipped centers. Participants are randomly assigned to either receive standard wound dressing or standard dressing combined with honey. The honey used is a quality-controlled product called Nusantara Honey, known for its wound healing properties and cost-effectiveness. The comparison treatment involves a PHMB solution, an antimicrobial agent effective against certain bacteria involved in these infections. Treatments and wound care continue until healing. During the study, wound healing is monitored by assessing wounds and bacterial presence on days 1, 7, and 14 after the abscess is opened. Tissue samples are also taken on days 1 and 14 to study cytokine and growth factor expression related to healing. The study tracks patient progress through wound assessments, measurements, and laboratory tests to evaluate the effectiveness and safety of honey in this treatment setting.

This clinical trial investigates the safety and potential benefits of a single intra-renal injection of allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) in adults aged 40 to 65 years with diabetic nephropathy, a common complication of diabetes leading to kidney failure. The study addresses whether UC-MSC therapy is safe and can improve kidney function and reduce inflammation over a 12-month follow-up. This trial is an open-label, single-arm study aiming to provide early human data on this novel cell-based therapy. Participants will receive one dose of UC-MSCs at 1 x 10^6 cells per kilogram of body weight, administered directly into the kidney under imaging guidance. No other treatments are compared in this study. After the injection, participants will have scheduled visits at 1, 3, 6, 9, and 12 months to monitor changes and safety. During follow-up visits, researchers will evaluate kidney function using tests such as estimated glomerular filtration rate (eGFR), serum creatinine, and urine albumin-to-creatinine ratio. They will also measure inflammatory markers like TNF-alpha and IL-10, and carefully track any adverse events or serious adverse events throughout the 12 months. The study results will be compared to baseline measurements taken before the treatment to assess any changes post-therapy.

Researchers are studying the effects of a combination therapy using dlbs 3233 and clomifen citrate compared to clomifen citrate alone in women with Polycystic Ovary Syndrome (PCOS). The study focuses on how these treatments affect insulin resistance, follicle maturation, and menstrual cycle regulation. It is an early phase 1 trial conducted at Muhammadiyah Asri Medical Center Hospital. Participants receive either the combination therapy of dlbs 3233 and clomifen citrate or clomifen citrate alone. The study aims to observe changes in key health markers related to PCOS, such as insulin resistance measured by HOMA-IR and serum AMH concentration, which are assessed at the start and after three months of treatment. During the study, participants are monitored for changes in these markers on the third day of their menstrual cycle at baseline and after three months of treatment. Researchers evaluate the impact of the therapies on menstrual cycle control and weight loss. The total duration of participation includes these assessments and treatment periods, with a focus on safety and effectiveness markers.